Rewiring Antitumor Immunity: Targeting CLDN18.2 with Conditional 4-1BB Activation
Claudin 18.2 has emerged as a validated target in solid tumors, spurring next-generation therapies. Bispecific antibodies linking Claudin 18.2 to conditional 4-1BB activation offer a novel approach to enhance T-cell function. By confining costimulation to the tumor microenvironment, they aim to boost efficacy while limiting systemic toxicity. See related article by Ku et al., p. 4944.
Authors
- G. Pretelli (ORCID: https://orcid.org/0000-0002-5550-1211)
- Elena Garralda (ORCID: https://orcid.org/0000-0002-4412-7842)
Institutions
- Hebron University (PS)
- Vall d'Hebron Institut de Recerca (ES)
- CIBBIM-Nanomedicine (ES)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2554
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundación BBVA
- Banco Bilbao Vizcaya Argentaria